Patents by Inventor Anantha Sudhakar

Anantha Sudhakar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF A COMPOUND
    Publication number: 20240059662
    Abstract: Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 22, 2024
    Inventors: Christopher R.H. Hale, Yingqing Ran, Anantha Sudhakar
  • Compounds, compositions and methods
    Patent number: 11851433
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
    Patent number: 11834438
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE
    Publication number: 20230271978
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Application
    Filed: January 11, 2023
    Publication date: August 31, 2023
    Inventor: Anantha Sudhakar
  • Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
    Patent number: 11427571
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: August 30, 2022
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT
    Publication number: 20220249479
    Abstract: The present disclosure relates to modified release formulations of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-IH-pyrazol-1-propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts thereof, and methods of treatment with the modified release formulations.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 11, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Harish RAVIVARAPU, Travis REMARCHUK, Anantha SUDHAKAR, Bradley K. WONG
  • Compounds, Compositions and Methods
    Publication number: 20220024938
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Compounds, compositions and methods
    Patent number: 11174262
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 16, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • POLYMORPHS AND SOLID FORMS OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF PRODUCTION
    Publication number: 20210087176
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 27, 2020
    Publication date: March 25, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS
    Publication number: 20210009566
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Application
    Filed: December 19, 2018
    Publication date: January 14, 2021
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
    Patent number: 10851088
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
    Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Compounds, Compositions and Methods
    Publication number: 20200079784
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • POLYMORPHS AND SOLID FORMS OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF PRODUCTION
    Publication number: 20190315723
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 17, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
    Patent number: 10370361
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 6, 2019
    Assignee: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • POLYMORPHS AND SOLID FORMS OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF PRODUCTION
    Publication number: 20190194170
    Abstract: The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 27, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20190084978
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 21, 2019
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1)
    Publication number: 20180353480
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 9969730
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 9839630
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 12, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Rahuman, Ramar Subbiah